SCHEMBL6403060

SCHEMBL6403060

O=C(CCCc1cccc(O)c1)c1c(O)cccc1P(=O)(O)O

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ACHE P22303 6/20 0.50
SGMS1 Q86VZ5 4/20 0.50
SGMS2 Q8NHU3 4/20 0.50
CBS P35520 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
MAPT P10636 2/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HTT P42858 1/20 0.40
KMT2A Q03164 1/20 0.40
ATM Q13315 1/20 0.40
MGLL Q99685 1/20 0.40
GAA P10253 1/20 0.40
SLC5A1 P13866 1/20 0.40
SLC5A2 P31639 1/20 0.40
DRD2 P14416 1/20 0.39
DRD1 P21728 1/20 0.39
TAAR1 Q96RJ0 1/20 0.39
TYR P14679 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6399719 0.92 SLC5A1 (0.48) ACHESGMS1SGMS2CBSHDAC6
SCHEMBL6397103 0.89 CBS (0.53) ACHESGMS1SGMS2CBSHDAC6
SCHEMBL6401949 0.87 ACHE (0.66) ACHESGMS1SGMS2CBSMAPT
SCHEMBL6404380 0.84 CTBP2 (0.42) ACHESGMS1SGMS2MAPTMEN1
SCHEMBL6395137 0.81 ACHE (0.47) ACHESGMS1SGMS2CBSHDAC6
SCHEMBL6403057 0.81 ACHE (0.50) ACHESGMS1SGMS2CBSHDAC6
SCHEMBL6403662 0.81 SLC5A1 (0.57) ACHESGMS1SGMS2CBSHDAC6
SCHEMBL6397688 0.81 HDAC6 (0.46) ACHESGMS1SGMS2HDAC6HTT
SCHEMBL6398689 0.81 HDAC6 (0.46) ACHESGMS1SGMS2CBSHDAC6
SCHEMBL6397026 0.79 ACHE (0.57) ACHESGMS1SGMS2MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans PEERCE BRIAN E (US) 2005-08-25 US disclosed
US-6787528-B2 THERAPY FOR KIDNEY DISEASES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2004-09-07 US disclosed
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2003-08-28 US disclosed
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation PEERCE BRIAN E (US) 2002-09-19 US disclosed
US-6355823-B1 MEMBRANE SUBSTRATE PHOSPHATED FOR DRUGS FOR GASTROINTESTINAL DISORDERS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2002-03-12 US disclosed
EP-1175425-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2002-01-30 EP disclosed
WO-2000043402-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2000-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 ACHE 4868/4885SGMS1 3968/4885SGMS2 4314/4885
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation SLC10A2, SLC34A3, SLC34A1 ACHE 4865/4885SGMS1 4101/4885SGMS2 4281/4885
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 ACHE 4868/4885SGMS1 3968/4885SGMS2 4314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.